Back to List View Graph View

Prostate cancer

Prostate cancer is a malignant disease of the prostate in which androgen receptor (AR) biology is an important focus of investigation, particularly in treatment-resistant and metastatic castration-resistant prostate cancer.

Where the papers sit

11 papers from the last 6 months study prostate cancer directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 4 observational · 4 human data · 2 preclinical · 1 unclassified

Themes 3 themes · 1 new direction

  • Prostate Cancer Assessment

    Prostate cancer assessment ranges from Gleason-grade progression and treatment decisions to urinary incontinence and radiotherapy safety. Interpretable machine learning emphasizes sensitivity, specificity, and validation for grading, while prostate volume and 5-alpha-reductase inhibitor use modify progression risk. Biological work links SAT1-driven spermine catabolism to reduced enzalutamide sensitivity and profiles bacterial genomes in saliva, tumour, and blood. The cluster has no single translational direction beyond broadening risk, treatment, and quality assessment.

    6 papers · 54.5%

  • Molecular Detection and Drug Discovery

    DNA methylation is being explored as a minimally invasive route to earlier, clinically significant prostate cancer detection. Seminal-fluid cfDNA and prediagnosis plasma cfDNA are the main signals, with emphasis on methylation signatures years before diagnosis. A separate study uses molecular design and docking to develop sulfonamide compounds with anticancer activity in prostate cancer cells. Thus the cluster combines emerging methylation biomarkers with early drug discovery rather than a single unified program.

    3 papers · 27.3%

  • Androgen Receptor Therapeutics

    Androgen receptor expression remains central to characterizing prostate tumours and their treatment context. Therapeutic degrader research shifts attention toward heterobifunctional and phthalimide degraders rather than conventional receptor inhibition alone. Hepatotoxicity and electron transport chain disruption recur as liabilities, making systematic toxicity mapping part of degrader development. The open question is whether targeted degradation can retain antitumour activity while widening the therapeutic window.

    2 papers · 18.2%

NEW DIRECTION

Prostate cancer is treated as a host-associated microbial ecosystem rather than solely as a tumor to diagnose, grade, treat, or monitor

The oral, blood, and prostate-tissue microbiome of patients with prostate cancer is the subject of the study, which reconstructs 249 highly complete bacterial genomes from whole-genome sequencing data and identifies previously unresolved oral bacterial species 42901952Oct. Whereas the other papers use prostate cancer as a disease whose tumor biology, treatment, toxicity, diagnosis, prognosis, or complications are being evaluated, this work makes the cancer setting a source for investigating microbial diversity and possible bacterial contributions to carcinogenesis. The resulting direction is metagenomic and causal investigation of host-associated microbes, not another application of the established tumor-centered frame.

Papers

The 11 papers from the last 6 months that study prostate cancer directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Prostate Cancer Assessment (6)
  1. Recovering anaerobic bacterial genomes in saliva, tumour and blood whole genome sequencing data from patients with prostate cancer. NPJ biofilms and microbiomes · 20 Oct 2026 PMID 42901952
  2. Can physics review catch prescription and PTV margin errors in fully automated radiotherapy plans? A hazard study. Journal of applied clinical medical physics · 28 Sept 2026 PMID 42805901
  3. SAT1 promotes prostate cancer progression and decreases enzalutamide sensitivity by enhancing spermine catabolism. Human cell · 16 Sept 2026 PMID 42744967
  4. Factors Influencing Postoperative Urinary Incontinence in Prostate Cancer Patients: A Retrospective Cohort Study. The American journal of nursing · 20 Aug 2026 PMID 42619203
  5. Toward Interpretable Machine Learning Models for Grading Prostate Cancer: A Multicenter Development and Validation Study. Clinical genitourinary cancer · 4 Jul 2026 PMID 42401511
  6. The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients With Prostate Cancer on Active Surveillance. The Journal of urology · 24 Jun 2026 PMID 42341197
Molecular Detection and Drug Discovery (3)
  1. Design, synthesis, DFT, molecular docking, POM analysis and anticancer for prostate cancer cells of new sulfonamide carrying drugs. Bioorganic chemistry · 22 Sept 2026 PMID 42772099
  2. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell genomics · 21 Sept 2026 PMID 42767223
  3. Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer. PloS one · 9 Sept 2026 PMID 42715227
Androgen Receptor Therapeutics (2)
  1. Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity. Nature chemical biology · 9 Oct 2026 PMID 42855516
  2. Prostatic Androgen Receptor Expression in Men with Prostate Cancer. The Nigerian postgraduate medical journal · 19 Aug 2026 PMID 42616976

By study type

Observational studies and case reports (4)
  1. Factors Influencing Postoperative Urinary Incontinence in Prostate Cancer Patients: A Retrospective Cohort Study. The American journal of nursing · 20 Aug 2026 PMID 42619203
  2. Prostatic Androgen Receptor Expression in Men with Prostate Cancer. The Nigerian postgraduate medical journal · 19 Aug 2026 PMID 42616976
  3. Toward Interpretable Machine Learning Models for Grading Prostate Cancer: A Multicenter Development and Validation Study. Clinical genitourinary cancer · 4 Jul 2026 PMID 42401511
  4. The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients With Prostate Cancer on Active Surveillance. The Journal of urology · 24 Jun 2026 PMID 42341197
Human data, design not indexed (4)
  1. Recovering anaerobic bacterial genomes in saliva, tumour and blood whole genome sequencing data from patients with prostate cancer. NPJ biofilms and microbiomes · 20 Oct 2026 PMID 42901952
  2. Can physics review catch prescription and PTV margin errors in fully automated radiotherapy plans? A hazard study. Journal of applied clinical medical physics · 28 Sept 2026 PMID 42805901
  3. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell genomics · 21 Sept 2026 PMID 42767223
  4. Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer. PloS one · 9 Sept 2026 PMID 42715227
Preclinical: animal, cell and lab studies (2)
  1. Design, synthesis, DFT, molecular docking, POM analysis and anticancer for prostate cancer cells of new sulfonamide carrying drugs. Bioorganic chemistry · 22 Sept 2026 PMID 42772099
  2. SAT1 promotes prostate cancer progression and decreases enzalutamide sensitivity by enhancing spermine catabolism. Human cell · 16 Sept 2026 PMID 42744967
Unclassified: not yet indexed with MeSH (1)
  1. Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity. Nature chemical biology · 9 Oct 2026 PMID 42855516